FELDAN THERAPEUTICS APPOINTS DR ROBERT J. WILLS TO BOARD OF DIRECTORS
by Feldan, on Jun 16, 2020 7:45:00 AM
Quebec City, Canada, June 16, 2020, Feldan Therapeutics, a biotechnology company focusing on the development of therapeutics based on its intracellular delivery technology, today announced the appointment of Dr. Robert J. Wills to its Board of Directors.
"We are honored to welcome Dr. Robert J. Wills to Feldan’s Board of Directors,” said François-Thomas Michaud, Co-founder and Chief Executive Officer of Feldan. "Dr. Wills’ strong scientific background and broad experience in the pharmaceutical industry bring highly valuable expertise to our board as we progress towards clinical development."
Dr. Robert Wills is the Chairman of Cymabay Therapeutics’ Board of Directors since October 2015, and has been a member of the Board since March 2015. Dr. Wills has more than 35 years of experience in the pharmaceutical industry and spent over 25 years at Johnson & Johnson, where he held positions as Senior Vice President of Global Development, Vice President of Alliance Management and a member of the Research & Development (R&D) Board of Directors. He has been responsible for the R&D pipeline and for managing strategic alliances for the Pharmaceutical Group worldwide, playing an active role in the negotiations of these alliances. Dr. Wills also served on several of the company boards and key pharmaceutical group decision-making committees.
Dr. Wills began his career at Hoffmann-LaRoche where he spent 10 years in several roles of scientific responsibility. He holds a B.S. in Biochemistry and an M.S. in Pharmaceutics from the University of Wisconsin, along with a Ph.D. in Pharmaceutics from the University of Texas.
"Feldan has the potential to develop treatments for diseases with unmet medical needs and change the way many others are treated by taking advantage of peptides and proteins specificity and safety,” said Dr. Wills. "I am pleased to join the Feldan’s Board of Directors and I look forward to helping advance the company’s pipeline and contributing to the achievement of its mission."
Feldan specializes in the development of treatments for diseases that mainly affect the lungs, skin, and the eyes. Their aim is to improve patients’ quality of life by delivering therapeutic proteins or peptides inside cells. The company, which is behind the design of a proprietary peptide-based intracellular delivery technology, is currently focusing on pre-IND filing and its Series B.
Feldan Therapeutics has developed the Feldan Shuttle, peptide-based technology that enables efficient intracellular delivery of peptides and biologics. The company's mission is to make intracellular delivery the future of medicine by developing leading-edge therapeutic applications based on its proprietary platform.
For more information: www.feldan.com
Francois-Thomas Michaud, PhD. Eng.
Feldan Therapeutics, Inc.
T: +1 418-872-7277